Purpose: To assess the prognostic effect of different levels of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Methods: IKZF1 Δ2-8/ALB deletions were quantified using multiplex real-time quantitative PCR in newly diagnosed pediatric BCP-ALL patients. Seventy-four patients with IKZF1 deletions ≥ 0.01% were included. Clinical characteristics, laboratory data, and treatment outcomes were analysed.
Results: The patients were divided into two groups: IKZF1 deletions < 1% (group A) and ≥ 1% (group B). Group B patients had a higher BCR-ABL1 positive rate than did group A patients. The proportions of patients who had an age at onset ≥10 years old, and white blood cell count ≥ 50×109/L were significantly higher in group B than in group A. The 3-year overall survival (OS) and 3-year event-free survival (EFS) rates in group B were 79 ± 8.8% and 62.4 ± 9.7%, respectively, being significantly lower than those in group A (97.7 ± 2.2% and 83.2 ± 5.8%, respectively). The level of IKZF1 deletions ≥ 1% and the central nervous system leukemia were independent risk factors of EFS.
Conclusions: Pediatric BCP-ALL patients with high levels of IKZF1 gene deletions have a poorer prognosis than those with low levels.
Figure 1
Figure 2
Figure 3
Loading...
Posted 19 Mar, 2021
Invitations sent on 16 Mar, 2021
On 16 Mar, 2021
Received 16 Mar, 2021
On 11 Mar, 2021
Posted 19 Mar, 2021
Invitations sent on 16 Mar, 2021
On 16 Mar, 2021
Received 16 Mar, 2021
On 11 Mar, 2021
Purpose: To assess the prognostic effect of different levels of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Methods: IKZF1 Δ2-8/ALB deletions were quantified using multiplex real-time quantitative PCR in newly diagnosed pediatric BCP-ALL patients. Seventy-four patients with IKZF1 deletions ≥ 0.01% were included. Clinical characteristics, laboratory data, and treatment outcomes were analysed.
Results: The patients were divided into two groups: IKZF1 deletions < 1% (group A) and ≥ 1% (group B). Group B patients had a higher BCR-ABL1 positive rate than did group A patients. The proportions of patients who had an age at onset ≥10 years old, and white blood cell count ≥ 50×109/L were significantly higher in group B than in group A. The 3-year overall survival (OS) and 3-year event-free survival (EFS) rates in group B were 79 ± 8.8% and 62.4 ± 9.7%, respectively, being significantly lower than those in group A (97.7 ± 2.2% and 83.2 ± 5.8%, respectively). The level of IKZF1 deletions ≥ 1% and the central nervous system leukemia were independent risk factors of EFS.
Conclusions: Pediatric BCP-ALL patients with high levels of IKZF1 gene deletions have a poorer prognosis than those with low levels.
Figure 1
Figure 2
Figure 3
Loading...